WO1999049892A3 - Use of active p40 conjugates for nasal delivery - Google Patents

Use of active p40 conjugates for nasal delivery Download PDF

Info

Publication number
WO1999049892A3
WO1999049892A3 PCT/FR1999/000703 FR9900703W WO9949892A3 WO 1999049892 A3 WO1999049892 A3 WO 1999049892A3 FR 9900703 W FR9900703 W FR 9900703W WO 9949892 A3 WO9949892 A3 WO 9949892A3
Authority
WO
WIPO (PCT)
Prior art keywords
nasal delivery
conjugates
active
membrane protein
fragment
Prior art date
Application number
PCT/FR1999/000703
Other languages
French (fr)
Other versions
WO1999049892A2 (en
Inventor
Christine Andreoni
Isabelle Rauly
Guyen Thien N
Jean-Francois Haeuw
Thierry Baussant
Original Assignee
Pf Medicament
Christine Andreoni
Isabelle Rauly
Guyen Thien N
Haeuw Jean Francois
Thierry Baussant
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament, Christine Andreoni, Isabelle Rauly, Guyen Thien N, Haeuw Jean Francois, Thierry Baussant filed Critical Pf Medicament
Priority to AU29391/99A priority Critical patent/AU764061B2/en
Priority to BR9909180-1A priority patent/BR9909180A/en
Priority to EP99910434A priority patent/EP1066054A2/en
Priority to CA002324477A priority patent/CA2324477A1/en
Priority to JP2000540854A priority patent/JP2002509897A/en
Publication of WO1999049892A2 publication Critical patent/WO1999049892A2/en
Publication of WO1999049892A3 publication Critical patent/WO1999049892A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention concerns the use of at least an enterobacteria outer membrane protein A fragment or a Klebsiella membrane protein fragment for preparing a pharmaceutical composition for nasal delivery, to improve a mammal's immunity to an antigen or a hapten.
PCT/FR1999/000703 1998-03-27 1999-03-26 Use of active p40 conjugates for nasal delivery WO1999049892A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU29391/99A AU764061B2 (en) 1998-03-27 1999-03-26 Use of active P40 conjugates for nasal delivery
BR9909180-1A BR9909180A (en) 1998-03-27 1999-03-26 Use of at least one fragment of a membrane protein and the process of preparing a protein or one of its fragments recombinantly
EP99910434A EP1066054A2 (en) 1998-03-27 1999-03-26 Use of active p40 conjugates for nasal delivery
CA002324477A CA2324477A1 (en) 1998-03-27 1999-03-26 Use of active p40 conjugates for nasal delivery
JP2000540854A JP2002509897A (en) 1998-03-27 1999-03-26 Use of active P40 conjugate for nasal delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9803814A FR2776521B1 (en) 1998-03-27 1998-03-27 USE OF P40 ACTIVE CONJUGATES BY NASAL
FR98/03814 1998-03-27

Publications (2)

Publication Number Publication Date
WO1999049892A2 WO1999049892A2 (en) 1999-10-07
WO1999049892A3 true WO1999049892A3 (en) 2000-03-30

Family

ID=9524572

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1999/000703 WO1999049892A2 (en) 1998-03-27 1999-03-26 Use of active p40 conjugates for nasal delivery

Country Status (8)

Country Link
EP (1) EP1066054A2 (en)
JP (1) JP2002509897A (en)
CN (1) CN1243569C (en)
AU (1) AU764061B2 (en)
BR (1) BR9909180A (en)
CA (1) CA2324477A1 (en)
FR (1) FR2776521B1 (en)
WO (1) WO1999049892A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2798857B1 (en) * 1999-09-23 2003-06-06 Pf Medicament USE OF AN OMPA MEMBRANE PROTEIN OF ENTEROBACTERIA ASSOCIATED WITH AN RSV IMMUNOGENIC PEPTIDE FOR THE PREPARATION OF NASAL ADMINISTRATIVE VACCINES
FR2805163A1 (en) * 2000-02-21 2001-08-24 Pf Medicament USE OF A ZWITTERGENT TYPE DETERGENT FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
CN1549726A (en) * 2000-07-31 2004-11-24 耶鲁大学 Innate immune system-directed vaccines
FR2827605B1 (en) 2001-07-20 2004-07-16 Pf Medicament NOVEL PEPTIDES DERIVED FROM RSV PROTEIN G AND THEIR USE IN A VACCINE
FR2828106A1 (en) * 2001-08-02 2003-02-07 Pf Medicament Composition containing peptide from low molecular weight outer membrane protein, useful for preparing vaccines against infections or cancer
CN112062820B (en) * 2020-08-24 2023-05-26 黑龙江八一农垦大学 Renaturation purification method of E.coli recombinant outer membrane protein A inclusion body protein

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0433225A1 (en) * 1989-12-06 1991-06-19 Ciba-Geigy Ag Process for the production of biologically active protein (e.g. TGF)
WO1995027787A1 (en) * 1994-04-06 1995-10-19 Pierre Fabre Medicament Peptide fragment of the respiratory syncytial virus g protein, immunogenic agent, pharmaceutical composition containing same, and preparation method
WO1996014415A1 (en) * 1994-11-07 1996-05-17 Pierre Fabre Medicament Carrier protein having an adjuvant effect, immunogenic complex containing same, preparation method therefor, nucleotide sequence and vaccine
FR2748476A1 (en) * 1996-05-07 1997-11-14 Pf Medicament IMMUNOGENIC COMPLEX, USE THEREOF, PREPARATION METHOD AND VACCINE CONTAINING THE SAME

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0433225A1 (en) * 1989-12-06 1991-06-19 Ciba-Geigy Ag Process for the production of biologically active protein (e.g. TGF)
WO1995027787A1 (en) * 1994-04-06 1995-10-19 Pierre Fabre Medicament Peptide fragment of the respiratory syncytial virus g protein, immunogenic agent, pharmaceutical composition containing same, and preparation method
WO1996014415A1 (en) * 1994-11-07 1996-05-17 Pierre Fabre Medicament Carrier protein having an adjuvant effect, immunogenic complex containing same, preparation method therefor, nucleotide sequence and vaccine
FR2748476A1 (en) * 1996-05-07 1997-11-14 Pf Medicament IMMUNOGENIC COMPLEX, USE THEREOF, PREPARATION METHOD AND VACCINE CONTAINING THE SAME

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ERDILE L F ET AL: "OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant", VACCINE, vol. 15, no. 9, June 1997 (1997-06-01), pages 988-995, XP004115364 *
HAEUW J F ET AL: "The recombinant Klebsiella pneumoniae outer membrane protein OmpA has carrier properties for conjugated antigenic peptides.", EUROPEAN JOURNAL OF BIOCHEMISTRY, (1998 JUL 15) 255 (2) 446-54., XP002116544 *
LEVI R ET AL: "Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes.", VACCINE, (1995 OCT) 13 (14) 1353-9, XP002088713 *
RAULY, I. ET AL: "P40: A promising new carrier protein.", RESEARCH IN IMMUNOLOGY, (JAN., 1998) VOL. 149, NO. 1, PP. 99. MEETING INFO.: EUROCONFERENCE ON NEW TRENDS IN VACCINE RESEARCH AND DEVELOPMENT: ADJUVANTS, DELIVERY SYSTEMS AND ANTIGEN FORMULATIONS PARIS, FRANCE FEBRUARY 26-28, 1998, XP002116543 *
VAN DE VERG L L ET AL: "Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models.", INFECTION AND IMMUNITY, (1996 DEC) 64 (12) 5263-8, XP002088714 *

Also Published As

Publication number Publication date
CN1301176A (en) 2001-06-27
WO1999049892A2 (en) 1999-10-07
JP2002509897A (en) 2002-04-02
EP1066054A2 (en) 2001-01-10
FR2776521B1 (en) 2000-12-15
AU2939199A (en) 1999-10-18
BR9909180A (en) 2000-12-05
AU764061B2 (en) 2003-08-07
FR2776521A1 (en) 1999-10-01
CA2324477A1 (en) 1999-10-07
CN1243569C (en) 2006-03-01

Similar Documents

Publication Publication Date Title
WO2001026693A3 (en) Manufacture of polyglutamate-therapeutic agent conjugates
ITRM910696A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE NASAL APPLICATION.
AU5945296A (en) Medicament for nasal administration
AU2001284483A1 (en) Remedies for heart failure
WO2002009754A1 (en) Novel remedies for cancer
CA2294783A1 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
AU4551199A (en) Novel therapeutic agents for membrane transporters
BR9916576A (en) Use of at-1 receptor antagonist or at-2 receptor modulator for the treatment of diseases associated with an increase in at-1 or at-2 receptors
AU8667298A (en) Self-binding shearform compositions
AU1263400A (en) Stable aqueous insulin preparations without phenol and cresol
WO1999049892A3 (en) Use of active p40 conjugates for nasal delivery
WO1997028104A3 (en) Buffer systems for use in stabilizing pharmaceutical preparations
AU2001295483A1 (en) Solid peptide preparations for inhalation, and the production thereof
WO1997023240A3 (en) Conjugate comprising an active agent, a polypeptide and a polyether
AU3697200A (en) Method for enhancement of delivery of thc by the administration of its prodrugs via the nasal route
AU2001258443A1 (en) Drug delivery device, especially for the delivery of gestodene
BR0212287A (en) Caspase-8 binding protein, its preparation and use
MXPA01003761A (en) Remedies for ocular diseases.
CA2218643A1 (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
CA2376847A1 (en) Complex of eletriptan and a cyclodextrin derivative
AU2001258442A1 (en) Drug delivery device, especially for the delivery of levonorgestrel
EP1044691A3 (en) Use of glycosaminoglycan lipid conjugates for inducing osteogenesis
AU5861396A (en) Stable aqueous formulations of 1alpha,25-dihydroxycholecalci ferol for parenteral administration
MD1473F2 (en) Antiherpetic remedy
AU2169799A (en) Pharmaceutical composition for nasal administration of thiocolchicoside

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99806265.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN JP MX US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2324477

Country of ref document: CA

Ref document number: 2324477

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/009490

Country of ref document: MX

Ref document number: 29391/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999910434

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09647309

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999910434

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 29391/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999910434

Country of ref document: EP